Fhl-1,一种新型的关键蛋白质,用于肺高血压
Grazyna Kwapiszewska1, Malgorzata Wygrecka, Leigh M Marsh
1Med Klinik II, University of Giessen Lung Center, Klinik Strasse 36, 35392 Giessen, Germany. Grazyna.Kwapiszewska@uglc.de
Circulation
|August 30, 2008
概括
研究人员将Fhl-1确定为肺高血压 (PH) 中升调的关键蛋白质. 这一发现为PH发展和这种严重疾病的潜在治疗目标提供了新的见解.
科学领域:
- 心血管研究研究心血管研究
- 肺部医学 肺部医学
- 分子生物学分子生物学
背景情况:
- 肺高血压 (PH) 是一种严重的疾病,其特点是血管重塑和右心力衰竭.
- 驱动PH相关的血管重塑的分子机制尚不清楚.
- 在疾病发作时确定关键因素对于理解PH至关重要.
研究的目的:
- 在PH的早期阶段,选肺组织中的蛋白质表达改变.
- 为了确定关键的分子参与者涉及到低氧诱导PH的发作.
主要方法:
- 2D聚烯胺凝电泳和MALDI-TOF分析以选蛋白质变化.
- 免疫组织化学,西部斑块和qPCR来确认蛋白质的表达.
- 使用人类肺动脉光滑肌细胞进行体外研究,以评估Fhl-1功能.
主要成果:
- 确定了36种蛋白质,在早期缺氧引起的PH中表达变化,包括明显升调的Fhl-1.
- 在各种PH模型中证实了Fhl-1上调 (低氧,单,SU5416) 和人类异常性肺动脉高血压.
- 证明Fhl-1调节肺动脉平滑肌肉细胞迁移和增殖,并确定Talin1作为一个相互作用的合作伙伴.
结论:
- Fhl-1是一种新型蛋白质,在多种形式的PH中受到显著调节.
- Fhl-1在肺高血压的发病过程中起作用.
- Fhl-1代表了PH和异常性肺动脉高血压的潜在治疗标.
相关概念视频
Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Hypertension and Regulation of Blood Pressure
3.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.8K
Hormonal Regulation of Blood Pressure
7.8K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
7.8K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
765
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
765
Heart Failure II: Pathophysiology
1.9K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Heart Failure V: Medical Management
626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626


